Latest revenue
$2.6M
as of 2026-03-31
Latest net income
$-27.9M
as of 2026-03-31
Net margin
-1077.4%
as of 2026-03-31
Community sentiment
Where do you think VYGR is heading?
Keep private notes on VYGR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
VYGR vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $206.9M
- Enterprise value
- $163.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.19×
- Dividend yield
- 0.0%
- 52-wk high
- $5.55
- 52-wk low
- $2.83
- Beta
- —
- Shares out
- 60.4M
What this company does
ITEM 1. BUSINESS We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic…
AI summary unavailable — showing raw filing excerpt
Generated from VYGR's filing dated 2026-03-09
Key risks
ITEM 1A. RISK FACTORS The following risk factors and other information in this Annual Report on Form 10-K, including our financial statements and related notes thereto, should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see the discussion under the caption “Forward-Looking Statements” in this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial…
AI summary unavailable — showing raw filing excerpt
Generated from VYGR's filing dated 2026-03-09
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.